WallStSmart

Cencora Inc. (COR)vsCosmos Health Inc. (COSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cencora Inc. generates 472909% more annual revenue ($328.68B vs $69.49M). COR leads profitability with a 0.8% profit margin vs -30.4%. COR earns a higher WallStSmart Score of 64/100 (C+).

COR

Buy

64

out of 100

Grade: C+

Growth: 7.3Profit: 6.0Value: 5.3Quality: 5.0
Piotroski: 4/9Altman Z: 4.36

COSM

Hold

41

out of 100

Grade: D

Growth: 6.7Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: -2.45
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CORSignificantly Overvalued (-58.6%)

Margin of Safety

-58.6%

Fair Value

$180.37

Current Price

$286.13

$105.76 premium

UndervaluedFair: $180.37Overvalued

Intrinsic value data unavailable for COSM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COR6 strengths · Avg: 9.2/10
Return on EquityProfitability
75.0%10/10

Every $100 of equity generates 75 in profit

EPS GrowthGrowth
128.3%10/10

Earnings expanding 128.3% YoY

Altman Z-ScoreHealth
4.3610/10

Safe zone — low bankruptcy risk

Market CapQuality
$55.67B9/10

Large-cap with strong market position

PEG RatioValuation
0.618/10

Growing faster than its price suggests

Free Cash FlowQuality
$1.17B8/10

Generating 1.2B in free cash flow

COSM2 strengths · Avg: 10.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
30.7%10/10

Revenue surging 30.7% year-over-year

Areas to Watch

COR4 concerns · Avg: 3.5/10
Price/BookValuation
16.4x4/10

Trading at 16.4x book value

Revenue GrowthGrowth
3.8%4/10

3.8% revenue growth

Profit MarginProfitability
0.8%3/10

0.8% margin — thin

Operating MarginProfitability
1.7%3/10

Operating margin of 1.7%

COSM4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$10.69M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-106.6%2/10

ROE of -106.6% — below average capital efficiency

Free Cash FlowQuality
$-1.08M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : COR

The strongest argument for COR centers on Return on Equity, EPS Growth, Altman Z-Score. PEG of 0.61 suggests the stock is reasonably priced for its growth.

Bull Case : COSM

The strongest argument for COSM centers on Price/Book, Revenue Growth. Revenue growth of 30.7% demonstrates continued momentum.

Bear Case : COR

The primary concerns for COR are Price/Book, Revenue Growth, Profit Margin. Debt-to-equity of 3.65 is elevated, increasing financial risk. Thin 0.8% margins leave little buffer for downturns.

Bear Case : COSM

The primary concerns for COSM are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

COR profiles as a value stock while COSM is a hypergrowth play — different risk/reward profiles.

COSM carries more volatility with a beta of 4.12 — expect wider price swings.

COSM is growing revenue faster at 30.7% — sustainability is the question.

COR generates stronger free cash flow (1.2B), providing more financial flexibility.

Bottom Line

COR scores higher overall (64/100 vs 41/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cencora Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.

Cosmos Health Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Cosmos Holdings Inc. is a vertically integrated pharmaceutical company. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?